| Protocol No. |
Title |
| OCR13631 |
Molecular Analysis for Therapy Choice (MATCH) |
| OCR15092 |
An Open-Label Study of Rovalpituzumab Tesirine in Subjects with Delta-Like Protein 3-Expressing Advanced Solid Tumors |
| OCR15173 |
An open-label Phase I dose-escalation study to evaluate the safety, tolerability, maximum tolerated dose, pharmacokinetics, and pharmacodynamics of the anti-C4.4a antibody drug conjugate BAY 1129980 in subjects with advanced solid tumors known to express C4.4a |
| OCR15873 |
A Phase 1/2 study exploring the safety, tolerability, and efficacy of INCAGN01876 in combination with immune therapies in subjects with advanced or metastatic malignancies |
| OCR16016 |
DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors |
| OCR16937 |
A Phase 1 Study of NLG802 for Adult Patients with Recurrent Advanced Solid Tumors |
